• Type: Serum contianing ant-FIPV.
• Status: Research
• Host Species for Licensed Use: Cat
• Antigen: FIPV (Weiss and Scott, 1981)
• Preparation: A healthy 5-month-old kitten with an F1PV serum antibody titer greater than 1:1600 served as the immune serum donor. This animal was an SPF kitten who had seroconverted by natural exposure to FIPV-shedding contact cats and had remained asymptomatic.(Weiss and Scott, 1981)
• Immunization Route: Intravenous injection (i.v.)
• Description: A serum containing anti-FIBV produced by an asymptomatic cat was injected into other cats.(Weiss and Scott, 1981)

• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Cat
• 3a gene engineering:
  • Type: Gene mutation
  • Description: This 3abc mutant is from Feline infectious peritonitis virus (Haijema et al., 2004).
  • Detailed Gene Information: Click Here.
• 3b gene engineering:
  • Type: Gene mutation
  • Description: This 3abc mutant is from Feline infectious peritonitis virus (Haijema et al., 2004).
  • Detailed Gene Information: Click Here.
• 3c gene engineering:
  • Type: Gene mutation
  • Description: This 3abc mutant is from Feline infectious peritonitis virus (Haijema et al., 2004).
  • Detailed Gene Information: Click Here.
• Immunization Route: Oronasal immunization

• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Cat
• 7a gene engineering:
  • Type: Gene mutation
  • Description: This 7ab mutant is from Feline infectious peritonitis virus (Haijema et al., 2004).
  • Detailed Gene Information: Click Here.
• 7b gene engineering:
  • Type: Gene mutation
  • Description: This 7ab mutant is from Feline infectious peritonitis virus (Haijema et al., 2004).
  • Detailed Gene Information: Click Here.
• Immunization Route: Oronasal immunization

• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: baculovirus-expressed N protein of the Type I FIPV strain KU-2 (Hohdatsu et al., 2003)
• N gene engineering:
  • Type: Recombinant protein preparation
  • Description: (Hohdatsu et al., 2003)
  • Detailed Gene Information: Click Here.
• Preparation: SF-9 cells cultured for 2 days were inoculated with the recombinant baculovirus. After absorption for 1 h, serum-free TC-100 medium was added to the cells and the cells were cultured at 27 °C. After culture for 96 h, the infected cells were recovered and washed with PBS. One milliliter of RSB buffer containing 0.2% NP-40 (0.01 M NaCl, 0.0015 M MgCl2, 0.01 M Tris–HCl, pH 7.4) was added to 1×107 cells and the cell suspension was kept at 4 °C for 30 min with occasional shaking. The cells were centrifuged at 800×g for 10 min. The precipitate was resuspended in PBS and used as recombinant N protein. Feline inactivated trivalent vaccine (Felidovac PCR; Intervet, The Netherlands), which is commercially available in Japan, was added to the recombinant N protein as an adjuvant. This feline inactivated trivalent vaccine contains 2% aluminum hydroxide gels and L80 as an adjuvant. (Hohdatsu et al., 2003)
• Immunization Route: subcutaneous injection
• Description: Cell lysate with baculovirus-expressed N protein of the Type I FIPV strain KU-2 recombinant vaccine was effective in preventing the progression of FIP without inducing antibody-dependent enhancement of FIPV infection in cats. (Hohdatsu et al., 2003)

Cat Response

• Vaccination Protocol: Serum was administered by slow intravenous injection and given at a dosage of 11 ml/kg per cat.(Weiss and Scott, 1981)
• Challenge Protocol: Six hr after administration of serum, the experimental kittens were inoculated intraperitoneally with 0.5 ml of FIPV- infected liver homogenate.
• Efficacy: Not protected, higher fatality rate than unvaccinated cats. (Weiss and Scott, 1981)

Cat Response

• Persistence: A 3abc mutant is attenuated in kittens (Haijema et al., 2004).
• Efficacy: A 3abc mutant induces protection in kittens from challenge with wild type FIPV (Haijema et al., 2004).

Cat Response

• Persistence: A 7ab mutant is attenuated in kittens (Haijema et al., 2004).
• Efficacy: A 7ab mutant induces protection in kittens from challenge with wild type FIPV (Haijema et al., 2004).

Cat Response

• Vaccination Protocol: Eight SPF cats aged 6 months and eight SPF cats aged 7–9 months were used in the first and second experiments, respectively. In both experiments, four cats were subcutaneously vaccinated three times with 3-week intervals. The same vaccination/challenge experiment was repeated twice. (Hohdatsu et al., 2003)
• Immune Response: In all vaccinated cats, the ELISA value against N protein began to increase on Day 6 after the challenge and the antibody responded earlier than that in the control cats. The anti-challenge virus (strain 79-1146) neutralizing antibody production converted to positive on Day 12 after the challenge in the vaccination and control groups, showing no significant difference between the two groups. (Hohdatsu et al., 2003)
• Challenge Protocol: As a challenge control, four cats received a subcutaneous administration of the SF-9 cell-derive d antigen, which was prepared as the recombinant N protein described above, with the adjuvant. Four weeks after the third vaccination, all cats were challenged oronasally with 105 TCID50 FIPV strain 79-1146. (Hohdatsu et al., 2003)
• Efficacy: Combining the results of the first and second experiments, the survival rates were 75% (6/8) and 12.5% (1/8) for the immunized and control groups, respectively. These survival rates were analyzed using the X2-test, and there was a significant difference (P<0.05). (Hohdatsu et al., 2003)